Delays in time to first lenalidomide prescription fill for multiple myeloma. Preliminary results of a combined home and rural outpatient clinic-based infusion program through the Veterans Health ...
Phase 2 evaluation of the nilotinib-paclitaxel combination in patients with rare solid tumors: Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors trial 1 (RARE ...
CEO Dr Ilian Iliev and Steve Cook, CEO of EMVC portfolio company DName-iT, talked with Proactive's Stephen Gunnion about ...
A new ultra-high-throughput sequencing platform boosts output, speeds turnaround, and improves genome coverage. It reduces costs, broadens clinical applications, and accelerates large-scale genomics ...
Life sciences and diagnostics company Revvity has had a busy couple of years, playing a major role in the next-generation sequencing-based screening of newborns to better enable healthcare ...
Like many cancer patients, Michael Wolff wanted answers. But, like many cancer patients in 2015, he wasn't getting them. After years of lymphoma treatment, the renowned jazz musician was still sick ...
CAMBRIDGE, England & SAN DIEGO, February 23, 2026--biomodal, an omics-based life sciences technology and analytics company, today announced at the AGBT 2026 General Meeting that biomodal’s duet ...
Janina Krumbeck, PhD, discusses the clinical advantages of next-generation sequencing over traditional culture and how this untargeted diagnostic approach provides comprehensive pathogen ...
Breast cancer remains one of the most prevalent and life-threatening forms of cancer, impacting millions worldwide. This malignancy's heterogeneity and complexity have long posed significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results